4D Molecular Therapeutics (FDMT) Enterprise Value (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Enterprise Value for 8 consecutive years, with -$390.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 21.61% year-over-year to -$390.9 million; the TTM figure through Mar 2026 stood at -$390.9 million (down 21.61% YoY), while the FY2025 annual figure was -$402.7 million, up 5.23% from the prior year.
• Enterprise Value climbed to -$390.9 million in Q1 2026 per FDMT's latest filing, from -$402.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$200.5 million in Q1 2023 and bottomed at -$541.9 million in Q2 2024.
• Historically, Enterprise Value has averaged -$337.9 million across 5 years, with a median of -$310.3 million in 2023.
• Annual changes were most pronounced in 2024 — Enterprise Value tumbled 162.36% — and 2025, when it surged 45.89%.
• 4D Molecular Therapeutics' Enterprise Value stood at -$213.6 million in 2022, then plunged by 34.97% to -$288.2 million in 2023, then tumbled by 47.41% to -$424.9 million in 2024, then increased by 5.23% to -$402.7 million in 2025, then gained by 2.92% to -$390.9 million in 2026.
• Business Quant data shows FDMT's Enterprise Value at -$390.9 million in Q1 2026, -$402.7 million in Q4 2025, and -$305.1 million in Q3 2025.